We are excited to present BBCIC's refreshed mission statement:

To generate reliable real-world evidence that examines the safety and effectiveness of biologics in order to improve public health.

A Note from the Executive Director

I hope you had some well-deserved time to relax and recharge over the holidays! 2020 was a challenging year for the world, and I can’t help but see the light that 2021 will bring on the horizon. We have all had to test our perseverance and stamina, and I’m proud of the accomplishments and contributions by the BBCIC community to continue pushing our research forward.

Read the full letter.

Current Research

G-CSF Comparative Safety and Effectiveness

Our partners at STATLOG have nearly completed preparing the ad hoc programming needed and we anticipate initial data will be compiled from the BBCIC Research Partners in March and April.

We are on schedule for data analysis and a draft report by the end of summer!

Insulins Utilization Analysis

Specifications are undergoing minor revisions to re-run this study to augment data that were collected a year ago as part of our effort to produce repeatable analyses to increase our longitudinal understanding of insulin use and select outcomes in our patient population.
Oncology Data Fitness Workgroup

A report describing the findings of the workgroup and recommended next steps for BBCIC in our efforts to enrich our existing data capabilities to better answer clinical effectiveness questions in oncology.

Trastuzumab Utilization Analysis

Data analysis is underway for our first look at utilization patterns and characteristics of patients in the BBCIC DRN who were treated with trastuzumab.

Research Plans

Trastuzumab Comparative Safety and Effectiveness

As the first priority determined by the BBCIC Science Committee, we will build off of the work by the oncology data feasibility workgroup to plan for our data needs, and to begin formulating a study plan.

Switching Patterns in Rheumatoid Arthritis

A group will be convened to define our specific research question, building on the work and recommendations from the Switching Workgroup, to design a study to evaluate treatment patterns, medication switching, and selected outcomes in patients treated for rheumatoid arthritis.

Publications

Three manuscripts have been published so far in 2021! Our looooong wait for peer review in 2020 is paying off in 2021! Congratulations!

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated with High Neutropenia Risk Chemotherapy


Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product

Abstracts

Two BBCIC abstracts have been accepted for poster presentation at AMCP 2021:

- Utilization patterns and characteristics of patients treated with the originator and follow-on insulin
• Aaron B. Mendelsohn, James Marshall, Cara L. McDermott, Pamala A. Pawloski, Jeffrey S. Brown, Catherine M. Lockhart.

*Drugs – Real World Outcomes*. Online First.

Utilization Patterns and Characteristics of Users of Biologic Anti-Inflammatory Agents in a Large, US Commercially Insured Population

• Aaron B. Mendelsohn, Young Hee Nam, James Marshall, Cara L. McDermott, Bharati Kochar, Michael D. Kappelman, Jeffrey S. Brown, Catherine M. Lockhart

*Pharmacology Research & Perspectives*. 2021;9.e00708
<table>
<thead>
<tr>
<th>Project</th>
<th>Planned</th>
<th>Analysis</th>
<th>Complete</th>
<th>Pending</th>
<th>Submitted</th>
<th>Accepted</th>
<th>Rejected</th>
<th>Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology Data Feasibility</td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AMCP 2021 April 13-16, 2021, Virtual</td>
</tr>
<tr>
<td>Insulin Utilization</td>
<td>1-2</td>
<td></td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>AMCP 2021 April 13-16, 2021, Virtual</td>
</tr>
<tr>
<td>G-CSF CER Study Design</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ISPOR 2021 May 17-20, 2021, Virtual</td>
</tr>
<tr>
<td>Trastuzumab Review - Gastric</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>ISPOR 2021 May 17-20, 2021, Virtual</td>
</tr>
<tr>
<td>Trastuzumab Review - Breast</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>TBD</td>
</tr>
<tr>
<td>Bevacizumab Review - Breast</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>TBD</td>
</tr>
<tr>
<td>Bevacizumab Review - AMD</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>TBD</td>
</tr>
<tr>
<td>Rituximab Review</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>TBD</td>
</tr>
<tr>
<td>Anti-Inflammatory Review</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>TBD</td>
</tr>
<tr>
<td>G-CSF CER Final Results</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td></td>
<td></td>
<td></td>
<td>TBD</td>
</tr>
</tbody>
</table>